Investigation into Stereoselective Pharmacological Activity of Phenotropil

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 5, 2011, Pages 407-412

  Zvejniece, Liga ^a   Svalbe, Baiba ^a,b   Veinberg, Grigory ^a   Grinberga, Solveiga ^a   Vorona, Maksims ^a   Kalvinsh, Ivars ^a   Dambrova, Maija ^a,c  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^b UNIVERSITY OF LATVIA   (Latvia)

^c RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

NOOTROPIC AGENT; PHENOTROPIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; ENANTIOMER; FORCED SWIMMING TEST; ISOMER; LOCOMOTION; MALE; MEMORY; MEMORY IMPROVING ACTIVITY; MOUSE; NONHUMAN; POSITIVE ION ELECTROSPRAY; PRIORITY JOURNAL; STEREOCHEMISTRY; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY, LIQUID; MALE; MEMORY; MICE; MICE, INBRED CBA; MICE, INBRED ICR; MOTOR ACTIVITY; PIRACETAM; STEREOISOMERISM; SWIMMING; TANDEM MASS SPECTROMETRY;

MUS;

EID: 80054061990     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00742.x     Document Type: Article

References (23)

1. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs 2010;70:287-312.
2. Tiurenkov IN, Bagmetov MN, Epishina VV. [Comparative evaluation of the neuroprotective activity of phenotropil and piracetam in laboratory animals with experimental cerebral ischemia]. Eksp Klin Farmakol 2007;70:24-9.
3. Winnicka K, Tomasiak M, Bielawska A. Piracetam - an old drug with novel properties? Acta Pol Pharm 2005;62:405-9.
4. Benesova O. Neuropathobiology of senile dementia and mechanism of action of nootropic drugs. Drugs Aging 1994;4:285-303.
5. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 1994;19:180-222.
6. Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord 2002;13:217-24.
7. Murphy N, Kazek MP, Van VB, Melac M, Souetre E. Economic evaluation of nootropil in the treatment of acute stroke in France. Pharmacol Res 1997;36:373-80.
8. Orgogozo JM. Piracetam in the treatment of acute stroke. Pharmacopsychiatry 1999;32(Suppl. 1):25-32.
9. Brandao F, Paula-Barbosa MM, Cadete-Leite A. Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. Alcohol 1995;12:279-88.
10. Paula-Barbosa MM, Brandao F, Pinho MC, Andrade JP, Madeira MD, Cadete-Leite A. The effects of piracetam on lipofuscin of the rat cerebellar and hippocampal neurons after long-term alcohol treatment and withdrawal: a quantitative study. Alcohol Clin Exp Res 1991;15:834-8.
11. Bel'skaia GN, Ponomareva IV, Lukashevich IG, Tikhomirova IN. [Complex treatment of epilepsy with phenotropil]. Zh Nevrol Psikhiatr Im SS Korsakova 2007;107:40-3.
12. Lybzikova GN, Iaglova Z, Kharlamova I. [The efficacy of phenotropil in the complex treatment of epilepsy]. Zh Nevrol Psikhiatr Im SS Korsakova 2008;108:69-70.
13. Gower AJ, Noyer M, Verloes R, Gobert J, Wulfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992;222:193-203.
14. Almeida JF, Grande M, Moran JR, Anaya J, Mussons ML, Caballero MC. Synthesis of the 3-hydroxy oxiracetam enantiomers, potential nootropic drugs. Tetrahedron: Asymmetry 1993;4:2483-94.
15. Veinberg G, Vorona M, Dambrova M, Karina L, Zvejniece L, Chernobrovijs A et al. N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use. 2007; EP2007/052424.
16. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36.
17. Venable N, Kelly PH. Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. Psychopharmacology 1990;100:215-21.
18. Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc (Baltim) 1957;46:208-9.
19. Dambrova M, Zvejniece L, Liepinsh E, Cirule H, Zharkova O, Veinberg G et al. Comparative pharmacological activity of optical isomers of phenibut. Eur J Pharmacol 2008;583:128-34.
20. Finney DJ. Probit Analysis. Cambridge University Press, Cambridge, UK, 1971;1-99.
21. Kovalev G, Ahapkina V, Abaimov D, Firstova I. Phenotropil like receptor modulation of synaptic neurotransmission. Clin Pharm 2007;4:22-6.
22. Marubio LM, Paylor R. Impaired passive avoidance learning in mice lacking central neuronal nicotinic acetylcholine receptors. Neuroscience 2004;129:575-82.
23. Narahashi T, Moriguchi S, Zhao X, Marszalec W, Yeh JZ. Mechanisms of action of cognitive enhancers on neuroreceptors. Biol Pharm Bull 2004;27:1701-6.